The future of heart failure with preserved ejection fraction : Deep phenotyping for targeted therapeutics.

"Declarations Conflict of interestF. R. Heinzel has received consulting fees from Abbott, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Menarini and Novartis, sponsoring from Bristol-Myers Squibb and Servier, and has been involved in research co-operations with Sanofi, Lexicon and Orion Pharma. S. J. Shah has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. Conflict of interest F. R. Heinzel has received consulting fees from Abbott, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Menarini and Novartis, sponsoring from Bristol-Myers Squibb and Servier, and has been involved in research co-operations with Sanofi, Lexicon and Orion Pharma. S. J. Shah has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics."

"Funding F. Heinzel is supported by research grants from the German Research Foundation (DFG: CRC1470 and HE 7737/4-1) and Novartis. S. Shah is supported by research grants from the National Institutes of Health (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer."